United States Molecular Diagnostics Market PPT 2024: Size, Growth, Demand and Forecast till 2032
                     United States Molecular 
Diagnostics Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
A cc o r d i ng  t o  t h e  l a t e s t  r e po r t  b y  IM A R C  G r o up ,  t i t l e d  " U n i t ed  S ta t e s  M o l e c u l a r  
D ia g n o s t i c s  M a rk e t :  I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  G r o wt h ,  Op p o r t u n i t y  a n d  
F o r e c a s t  2 0 2 4 - 2 0 3 2 , "  t h e  U n i te d  S ta t e s  m o l ec u l a r  d i a g n o s t i c s  ma r k e t  s i z e  i s  p r o j e c t e d  
t o  e x h i b i t  a  g ro w t h  ra t e  ( C A G R )  o f  5 .2 %  d u r i n g  2 02 4 - 2 03 2 .
Report T he  U n i t e d  S t a t e s  mo l e c u l a r  d i a g no s t i c s  m a r k e t  i s  w i t n e s s i ng  s i g n i f i c a n t  g r o w t h  d u e  to  i n c r e a s e d  d e ma n d  fo r  p e r so n a l i z ed  m e d i c i n e  a n d  a d v a nc e m en t s  i n  g e ne t i c  t e s t i n g  
t ec h n o l o g i e s .  T h e  r i s e  i n  i n f ec t i o u s  d i se a s e s  a n d  c a n c e r  c a s e s  d r i v e s  t he  a d o p t i o n  o f  
Highlight and mo l e c u l a r  d i a g no s t i c  t oo l s ,  as  th e s e  o f f e r  p r e c i s e  a n d  ea r l y  d e t e c t i o n ,  l e a d i n g  t o  b e t te r  
t r e a t me n t  ou t c o me s .  
C om p a n i e s  a r e  i n c r ea s i n g l y  i nv e s t i n g  i n  r e s ea r c h  a nd  d e ve l o p m e n t  t o  c r e a t e  i n no v a t i v e  
Description d i a gn o s t i c  s o l u t i o ns ,  i n c l u d i n g  ne x t - g en e r a t i o n  s e q u e nc i n g  a n d  po i n t - o f - c a r e  t e s t i n g .  
A dd i t i o n a l l y ,  r e g u l a t o r y  s up p o r t  a n d  f a v o r ab l e  re i m b u rs e m e n t  p o l i c i es  f u r t h e r  e n h a nc e  
ma r k e t  e x p a ns i o n .  T he  i n t eg r a t i o n  o f  A I  a n d  b i g  d a t a  an a l y t i c s  i n t o  d i a g n os t i c s  i s  a l s o  
r es h a p i n g  t h e  l an d s ca p e ,  o f f e r i n g  m o r e  a c c u ra t e  a nd  e f f i c i e n t  t e s t i n g  s o l u t i on s .
R eq u e s t  f o r  a  P D F  sa m p l e  o f  t h i s  re p o r t :  
h t t p s : / /w w w . i ma r c g r o u p . co m / u n i te d - s t a t e s -m o l e c u l a r - d i a gn o s t i c s - m a rk e t / r eq u e s ts a m p l e
Report Description
Uni ted  S ta tes  Mo lecu l ar  D i agnost ics  Market  T rends:
The  Un i ted  S t a t es  mo lecu la r  d iagnos t i cs  marke t  i s  be ing  p rope l led  by  the  g row ing  p reva lence  o f  i n fec t ious  d i seases ,  
gene t i c  d iso rders ,  and  cancer ,  l ead ing  to  an  i nc reased  demand  fo r  advanced d iagnos t i c  t oo l s .  The  ag ing  popu la t ion  
and t he  r i se  i n  chron ic  d iseases  are  f u r the r  f ue l ing  m arke t  expans ion ,  as  ea r l y  de t ec t ion  and persona l i zed  t rea tment  
become more  c ruc ia l .  Advances  i n  t echno logy ,  such  as  nex t -genera t ion  sequenc ing  and PCR-based  t echn iques ,  a re  
enhanc ing  t he  accu racy  and speed  o f  mo lecu la r  d iagnos t i cs ,  mak ing  t hem more  a t t rac t i ve  to  hea l t hca re  p rov ide rs .  
Regu la t o r y  suppor t  and  governmen t  in i t i a t i ves  a imed a t  improv ing  hea l thca re  in f r as t ruc tu re  a re  a lso  p lay ing  a  
s ign i f i can t  r o le  in  marke t  g rowth .  Add i t i ona l l y ,  t he  in teg ra t ion  o f  A I  and  mach ine  lea rn ing  in  d iagnos t i cs  i s  d r i v ing  
innova t i on ,  a l low ing  f o r  more  p rec ise  and  pred ic t i ve  ana lys is .  The sh i f t  t owards  po in t -o f - ca re  tes t ing  and  t he  g row ing  
adop t ion  o f  compan ion  d iagnos t i cs  in  persona l i zed  med ic ine  a re  o ther  key  t r ends  shap ing  the  marke t .  M oreover ,  t he  
inc reas ing  focus  on  prevent i ve  hea l thca re  and the  expans ion  o f  t e lemed ic ine  se rv ices  a re  b roaden ing  t he  app l i ca t ion  
o f  mo lecu la r  d iagnos t i cs ,  c rea t ing  new oppor t un i t i es  fo r  marke t  p layers .
Vi ew Report  TOC,  F igures and  Tab les :  h t tps: / / www. i marcgroup .com/un i ted -states -mo l ecu lar -d i agnost ics -market
Product Insights:
• Reagents and K i ts
• Instruments
• Software and Services
 
Technology Insights:
• Polymerase Chain React ions (PCR)
Report • Hybridizat ion
• DNA Sequencing
Segmentation
• Microarray
• Isothermal  Nucleic  Acid Ampl ifi cat ion 
Technology ( INAAT)
• Others
Application Insights:
• Infect ious Diseases Diagnost ics
• Oncology
• Genetic Test ing
• Blood Screening
• Others
End Users Insights:
Report • Hospitals
• Laboratories
Segmentation
• Others
Regional Insights:
• Northeast
• Midwest
• South
• West
How has the United States molecular diagnostics market 
performed so far and how will it perform in the coming 
years?
What has been the impact of COVID-19 on the United States 
molecular diagnostics market?
Key 
Questions What is the breakup of the United States molecular diagnostics market on the basis of product?
Answered in 
What is the breakup of the United States molecular 
the Report diagnostics market on the basis of technology?
What is the breakup of the United States molecular 
diagnostics market on the basis of application?
What is the breakup of the United States molecular 
diagnostics market on the basis of end user?
What are the various stages in the value chain of the United 
States molecular diagnostics market?
What are the key driving factors and challenges in the 
United States molecular diagnostics market?
Key 
Questions What is the structure of the United States molecular diagnostics market and who are the key players?
Answered in 
the Report What is the degree of competition in the United States molecular diagnostics market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4    U n i t e d  S t a t e s  M o l e c u l a r  D i a g n o s t i c s  M a r k e t  -  I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     M a r k e t  D y n a m i c s
    4 . 3     I n d u s t r y  T r e n d s
    4 . 4     C o m p e t i t i v e  I n t e l l i g e n c e
5    U n i t e d  S t a t e s  M o l e c u l a r  D i a g n o s t i c s  M a r k e t  L a n d s c a p e
    5 . 1     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
    5 . 2     M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6    U n i t e d  S t a t e s  M o l e c u l a r  D i a g n o s t i c s  M a r k e t  -  B r e a k u p  b y  P r o d u c t
    6 . 1     R e a g e n t s  a n d  K i t s
        6 . 1 . 1  O v e r v i e w
        6 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 2     I n s t r u m e n t s
        6 . 2 . 1  O v e r v i e w
        6 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
       
     6 . 3     S o f t w a r e  a n d  S e r v i c e s  
        6 . 3 . 1  O v e r v i e w
        6 . 3 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 3 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
7    U n i t e d  S t a t e s  M o l e c u l a r  D ia g n o s t i c s  M a r k e t  -  B r e a k u p  b y  
T e c h n o l o g y  
     7 . 1     P o l y me r a s e  C h a i n  R e a c t i o n s  ( P C R )
        7 . 1 . 1  O v e r v i e w
        7 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
Table of     7 . 2     H y b r i d i z a t i o n        7 . 2 . 1  O v e r v i e w
        7 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
Contents     7 . 3     D N A  S e q u e n c i n g
        7 . 3 . 1  O v e r v i e w
        7 . 3 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 3 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 4     M i c r o a r r a y
        7 . 4 . 1  O v e r v i e w
        7 . 4 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 4 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 5     I s o t h e r m a l  N u c l e i c  A c i d  A m p l i f i c a t i o n  T e c h n o l o g y  
( I N A A T )
        7 . 5 . 1  O v e r v i e w
        7 . 5 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 5 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )     
F o r  m o r e  i n f o r m a t io n ,  v i s i t :  
ht tps : / /www. imarcgroup .com/un i ted-s ta tes -molecu lar-d iagn
os t i cs -market / toc
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: